Did Jim Cramer Nail All These 9 Stock Predictions?

2. Recursion Pharmaceuticals Inc. (NASDAQ:RXRX)

Number of Hedge Fund Holders: 21

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX), a clinical-stage biotech integrating AI into drug discovery, was mentioned by a caller seeking Cramer’s take. Cramer clearly considered it a cutting-edge name with long-term potential at the time. Here’s what he replied with:

“I’ve been waiting for someone to bring this stock up. Why? Because when I was at Nvidia for the great GTC conference, they talked about this company endlessly. I think you have a real winner. The stock went up after around the conference and has come right back down. Recursion is for me. [hits buy button]”

Unfortunately, the stock has since dropped by 26.91%, making his call a clear miss.

Nonetheless, Cramer still likes Recursion Pharmaceuticals Inc. (NASDAQ:RXRX), having talked about a potential upcoming catalyst for the stock. Here’s his analysis from April 11:

“Alright, we got some news from the FDA that’s impacting the stock. I don’t normally do small caps, but there’s an FDA announcement, plan to phase out animal testing requirements for monoclonal antibodies. By the way, Regeneron, biggest in that. But what they’re gonna do is you gotta do it AI. And the AI company that has it, I’ve had them on, is Recursion Pharmaceuticals, RxRx, backed by Jensen Huang and NVIDIA. And they’re going to be the winner in how we decide much faster to have drugs approved in this country. It’s the first real deregulation I’ve seen. Congratulations to the people who are trying to deregulate.”